Top Markets
#1 Akedo Akedo +70.44%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.33%
#4 Cross Cross +45.97%
#5 Velvet Velvet +34.78%
#6 Black Phoenix Black Phoenix +34.22%
#7 OVERTAKE OVERTAKE +21.57%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.16%
#9 Movement Movement +13.74%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +13.14%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Redx Pharma Plc Redx Pharma Plc

Redx Pharma Plc

REDX
Rank in Stocks #38811
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in... Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
Share Price
$0.20410523
Last synced: 2024-04-30
Market Cap
$793.94K
Change (1 day)
42.54%
Change (1 year)
0.00%
Country
GB
Trade Redx Pharma Plc (REDX)

Category

Healthcare
Revenue for Redx Pharma Plc (REDX)
Revenue in Aug 2026 TTM: 0
According to Redx Pharma Plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Redx Pharma Plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE